Publication date: Aug 01, 2025
Nirmatrelvir/ritonavir, remdesivir, and molnupiravir are recommended antiviral therapies for non-severe COVID-19 patients at high risk of disease progression. This study evaluated the real-world effectiveness and economic impact of these three antiviral regimens in Thailand. This retrospective observational study was conducted at Siriraj Hospital, Thailand. Eligible patients were ambulatory adults (≥15 years old) with non-severe COVID-19 infection, presenting ≥1 risk factor for disease progression, and receiving ≥1 dose of nirmatrelvir/ritonavir, remdesivir, or molnupiravir within 5 days of symptom onset. Subsequently, an economic analysis was performed using data from this study and landmark clinical trials. During the study period (March-August 2022), there were 374 eligible patients: 104 patients (30. 0 %), 114 patients (33. 0 %), and 127 patients (37. 0 %) received nirmatrelvir/ritonavir, remdesivir, and molnupiravir, respectively. The unfavorable clinical outcomes were significantly higher in the remdesivir group (12. 28 %), compared to the nirmatrelvir/ritonavir group (2. 88 %), and the molnupiravir group (4. 72 %) by pairwise comparison (p-value
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Ritonavir |
| disease | MESH | COVID-19 |
| disease | MESH | disease progression |
| disease | MESH | infection |
| disease | IDO | symptom |
| drug | DRUGBANK | Adenosine phosphate |
| drug | DRUGBANK | L-Alanine |
| drug | DRUGBANK | Cytidine |
| drug | DRUGBANK | L-Leucine |
| drug | DRUGBANK | Proline |